drugset / Trial / NCT02245516
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
RandomizedParallel-groupSingle-blindTreatment
Summary
The primary objectives of the study are to evaluate the safety and effect of KPI-121 0.25% ophthalmic suspension and KPI-121 1.0% ophthalmic suspension on intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or Diabetic Macular Edema.
Timeline
- Start
- 2014-07
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Loteprednol Etabonate | Other / unclassified | 0.25 % | Topical |
| Comparator | Loteprednol Etabonate | Other / unclassified | 1 % | Topical |